Unknown

Dataset Information

0

First-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2- Breast Cancer.


ABSTRACT: Women with hormone receptor-positive, human epidermal growth factor receptor 2- negative breast cancer-the most common subtype-have new options as palbociclib and similar drugs debut. This article outlines the rationale and evidence for their use.

SUBMITTER: McCain J 

PROVIDER: S-EPMC4517534 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

First-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2- Breast Cancer.

McCain Jack J  

P & T : a peer-reviewed journal for formulary management 20150801 8


Women with hormone receptor-positive, human epidermal growth factor receptor 2- negative breast cancer-the most common subtype-have new options as palbociclib and similar drugs debut. This article outlines the rationale and evidence for their use. ...[more]

Similar Datasets

| S-EPMC6449170 | biostudies-literature
| S-EPMC10102847 | biostudies-literature
| S-EPMC4534142 | biostudies-literature
| S-EPMC8202336 | biostudies-literature
| S-EPMC6241542 | biostudies-literature
| S-EPMC7989035 | biostudies-literature
| S-EPMC5818877 | biostudies-literature
| S-EPMC7695984 | biostudies-literature
| S-EPMC5652078 | biostudies-literature
| S-EPMC10297170 | biostudies-literature